Sign up to save your podcasts
Or
Share NADIM II & Favorable Risk RCC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NADIM II & Favorable Risk RCC
This episode...
More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II.
Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.)
NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530
FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030
View all episodes
By John Bossaer
4.9
185185 ratings
This episode...
More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II.
Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.)
NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530
FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030
More shows like OncoPharm
View all
JAMA Clinical Reviews
500 Listeners
The Daily
113,004 Listeners
Up First from NPR
56,983 Listeners
Armchair Expert with Dax Shepard
69,699 Listeners
ASCO Guidelines
45 Listeners
The Peter Attia Drive
8,688 Listeners
OncLive® On Air
22 Listeners
Raising Good Humans
1,895 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Huberman Lab
29,364 Listeners
The Money with Katie Show
1,557 Listeners
Two Onc Docs
195 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
45 Listeners
WolverHeme Happy Hour
30 Listeners
Good Hang with Amy Poehler
13,054 Listeners